株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

造影剤の世界市場の予測 〜2021年:ヨード・ガドリニウム・バリウム・マイクロバブル

Contrast Media/Contrast Agent Market by Type (Iodinated, Gadolinium, Barium, & Microbubble), Procedure (X-Ray/CT, MRI, & Ultrasound) & Application (Radiology, Interventional Radiology, & Interventional Cardiology) - Global Forecasts to 2021

発行 MarketsandMarkets 商品コード 259150
出版日 ページ情報 英文 162 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.77円で換算しております。
Back to Top
造影剤の世界市場の予測 〜2021年:ヨード・ガドリニウム・バリウム・マイクロバブル Contrast Media/Contrast Agent Market by Type (Iodinated, Gadolinium, Barium, & Microbubble), Procedure (X-Ray/CT, MRI, & Ultrasound) & Application (Radiology, Interventional Radiology, & Interventional Cardiology) - Global Forecasts to 2021
出版日: 2016年10月19日 ページ情報: 英文 162 Pages
概要

世界の造影剤市場の規模は予測期間中4.1%のCAGR (年間複合成長率) で推移し、2016年の44億6000万米ドルから、2021年には54億4000万米ドルの規模に成長すると予測されています。造影剤の承認数の増加や民間および公共の診断センターの増加などの要因が各種診断画像モダリティへの需要を推進しており、企業による積極的な製品開発や各種造影剤の用途に関する研究の拡大も将来の新たな市場機会の創出に貢献するものと期待されています。

当レポートでは、世界の各種造影剤の市場について調査し、造影剤の種類と概要、市場成長への各種影響因子および市場機会の分析、パイプラインの動向、製品タイプ・医療処置・投与経路・適応症・用途など各種区分別の市場分析および市場成長予測、地域および主要国の動向、競合環境と市場シェア、主要企業のプロファイルなどをまとめています。

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

  • 市場概要
  • 製品タイプ・投与経路別市場
  • 地域概要
  • 適応症別市場の実績・予測

第5章 造影剤の世界市場:概要

  • イントロダクション
  • 市場力学
    • 成長推進因子
    • 成長阻害因子
    • 市場機会
    • 課題

第6章 パイプライン分析

  • イントロダクション
    • 造影剤を利用した臨床試験
    • 製品パイプライン

第7章 造影剤の世界市場:タイプ別

  • イントロダクション
  • ヨード造影剤
  • ガドリニウム造影剤
  • マイクロバブル造影剤
  • バリウム造影剤

第8章 造影剤の世界市場:医療処置別

  • イントロダクション
  • X線/CT
  • MRI
  • 超音波

第9章 造影剤の世界市場:投与経路別

  • イントロダクション
  • 注射
  • 経口
  • 直腸注入
  • 尿道注入

第10章 造影剤の世界市場:適応症別

  • イントロダクション
  • 心臓血管疾患
  • 胃腸疾患
  • 神経疾患
  • 腎臓疾患
  • 筋骨格系疾患

第11章 造影剤の世界市場:用途別

  • イントロダクション
  • 放射線医学
  • IVC (インターベンショナルカーディオロジー)
  • IVR (インターベンショナルラジオロジー)

第12章 造影剤の世界市場:地域別

  • イントロダクション
  • 北米
  • 欧州
  • アジア太平洋
  • その他の地域
    • ラテンアメリカ
    • 中東
    • アフリカ

第13章 競合環境

  • 概要
  • 市場シェア分析
    • BAYER HEALTHCARE
    • GE HEALTHCARE
  • 競合状況・動向
    • 市場の発展 (製品の承認)
    • 合意・協力・提携・契約
    • 拡張
    • その他

第14章 企業プロファイル

  • GE HEALTHCARE
  • BAYER AG
  • BRACCO IMAGING S.P.A.
  • GUERBET GROUP
  • LANTHEUS MEDICAL IMAGING (LANTHEUS HOLDINGS, INC.)
  • NANOPET PHARMA GMBH
  • CMC CONTRAST AB
  • 第一三共
  • SUBHRA PHARMA PRIVATE LIMITED
  • SPAGO NANOMEDICAL AB
    • 概要
    • 製品・サービス
    • 戦略
    • 発展動向、など

第15章 付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: MD 3577

The global contrast media/contrast agents market is projected to reach USD 5.44 billion by 2021 from USD 4.46 billion in 2016 growing at a CAGR of 4.1% during the forecast period.

The contrast media/contrast agents market has witnessed various advancements in products and their approvals to meet the needs of patients and radiologists worldwide. These advancements have led to the improved use of many existing contrast agents as well as the introduction of new ones.

Factors such as increasing approvals for contrast agents and increase in the number of public and private diagnostic centers to improve diagnostic imaging services are driving the demand of various diagnostic imaging modalities. Moreover, strong product pipelines of the market players, coupled with the increasing research studies regarding applications of various contrast agents, are expected to create opportunities for market growth in the near future. However side effects, adverse and allergic reactions associated with contrast agents are restraining the growth of the market to a certain extent.

In 2016, the iodinated contrast media segment expected to account for the largest share of the global contrast media/contrast agents market, among type of contrast media; the injectable contrast media segment is expected to account for the largest share of the global contrast media/contrast agents market, among the routes of administration; the X-ray/CT segment is expected to dominate the global contrast media/contrast agents market, among procedures; the cardiovascular disorders segment is expected to account for the largest share of the global contrast media/contrast agents market, among indications; and the radiology segment is expected to dominate the contrast media/contrast agents market, among applications.

In 2016, North America is estimated to be the largest market for contrast media/contrast agents, globally, followed by Europe, Asia-Pacific, and Rest of the World (RoW). In the coming years, the contrast media/contrast agents market is expected to witness the highest growth rate in the European region. The high growth in this region can be attributed to the increasing research & development investments by market players, increasing incidences and prevalence of cancer, and increasing number of MRI and CT scanners.

The market witnesses high competitive intensity, as there are several big and many small firms with similar product offerings. These companies adopt various strategies such as product approvals, agreements, collaborations, contract, and partnerships; expansions; and other strategies (divestment, grant, insurance coverage approval and acquisition) to increase their market shares and establish a strong foothold in the global market.

In-depth interviews were conducted with CEOs, Sales and Marketing Directors, other innovation and technology directors, and executives from various key organizations operating in the contrast media/contrast agents market.

  • By Company Type: Tier 1: 52%, Tier 2: 39%, Tier 3: 9%
  • By Designation: Director Level: 19%, C-Level: 28%, Others: 53%
  • By Region: North America: 27%, Europe: 27%, APAC: 30%, RoW: 16%

The prominent players in the global contrast media/ contrast agents market include Bayer HealthCare (Germany), GE Healthcare (U.S.), Guerbet Group (France), Bracco Imaging S.p.A. (Italy) in 2015. These companies are dominant in the contrast media/contrast agents market mainly due to their well-established presence in the field of contrast media, presence in over 50 countries, high R&D investments, and strong sales and distribution force. Other players operating in this market include Lantheus Medical Imaging (U.S.), nanoPET GmbH (Germany), CMC Contrast AB (Sweden), Daiichi Sankyo (Japan), and Subhra Pharma Private Limited (India).

Research Coverage:

The report provides a picture of the contrast media/contrast agents market across different industry verticals and regions. It aims at estimating the market size and future growth potential of this market across different segments such as by type, procedure, route of administration, indication, application, and regions. Furthermore, the report also includes an in-depth competitive analysis of the key players in the market along with their company profiles, recent developments, product pipeline and key market strategies.

Reasons to Buy the Report:

The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn helps the firms to garner a greater share of the concerned market. Firms purchasing the report could use any one or a combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.

The report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on the product portfolios offered by the top players in the contrast media/contrast agents market - the report analyzes the contrast media/contrast agents market, on the basis of type, route of administration, procedure, indication, and application
  • Product Development/Innovation: Detailed insights on the upcoming technologies, research & development activities, product approvals, and new product launches in the contrast media/contrast agents market
  • Market Development: Comprehensive information about the lucrative emerging markets - the report analyzes the markets for various contrast media/contrast agents across regions
  • Market Diversification: Exhaustive information about new products, untapped regions, recent developments, and investments in the contrast media/contrast agents market
  • Competitive Assessment: In-depth assessment of the market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the contrast media/contrast agents market

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF THE STUDY
  • 1.2. MARKET DEFINITION
  • 1.3. MARKET SCOPE
    • 1.3.1. MARKETS COVERED
    • 1.3.2. YEARS CONSIDERED FOR THE STUDY
  • 1.4. CURRENCY
  • 1.5. LIMITATIONS
  • 1.6. STAKEHOLDERS

2. RESEARCH METHODOLOGY

  • 2.1. RESEARCH METHODOLOGY STEPS
  • 2.2. SECONDARY AND PRIMARY RESEARCH METHODOLOGY
    • 2.2.1. SECONDARY RESEARCH
      • 2.2.1.1. Key data from secondary sources
    • 2.2.2. PRIMARY RESEARCH
      • 2.2.2.1. Key insights from primary sources
      • 2.2.2.2. Key industry insights
  • 2.3. MARKET SIZE ESTIMATION METHODOLOGY
  • 2.4. MARKET FORECAST METHODOLOGY
  • 2.5. MARKET DATA VALIDATION AND TRIANGULATION
  • 2.6. ASSUMPTIONS

3. EXECUTIVE SUMMARY

  • 3.1. INTRODUCTION
  • 3.2. CONCLUSION

4. PREMIUM INSIGHTS

  • 4.1. CONTRAST MEDIA: MARKET OVERVIEW
  • 4.2. CONTRAST MEDIA MARKET, BY TYPE AND ROUTE OF ADMINISTRATION (2016)
  • 4.3. GEOGRAPHIC SNAPSHOT: CONTRAST MEDIA MARKET
  • 4.4. GLOBAL CONTRAST MEDIA MARKET, BY INDICATION (2016 VS. 2021)

5. MARKET OVERVIEW

  • 5.1. INTRODUCTION
  • 5.2. MARKET DYNAMICS
    • 5.2.1. DRIVERS
      • 5.2.1.1. Large number of approvals for contrast agents
      • 5.2.1.2. Increasing number of public and private diagnostic centers
    • 5.2.2. RESTRAINT
      • 5.2.2.1. Side effects and allergic reactions associated with contrast agents
    • 5.2.3. OPPORTUNITY
      • 5.2.3.1. Increasing number of research and funding activities for contrast agents
    • 5.2.4. CHALLENGES
      • 5.2.4.1. Development of gamma and neutron imaging solutions
      • 5.2.4.2. Need for highly skilled professionals

6. PIPELINE ASSESSMENT

  • 6.1. INTRODUCTION
    • 6.1.1. CLINICAL TRIALS USING CONTRAST MEDIA
    • 6.1.2. PRODUCT PIPELINE

7. GLOBAL CONTRAST MEDIA/AGENTS MARKET, BY TYPE

  • 7.1. INTRODUCTION
  • 7.2. IODINATED CONTRAST MEDIA
  • 7.3. GADOLINIUM-BASED CONTRAST MEDIA
  • 7.4. MICROBUBBLE CONTRAST MEDIA
  • 7.5. BARIUM- BASED CONTRAST MEDIA

8. GLOBAL CONTRAST MEDIA/AGENTS MARKET, BY MEDICAL PROCEDURE

  • 8.1. INTRODUCTION
  • 8.2. X-RAY/CT
  • 8.3. MRI
  • 8.4. ULTRASOUND

9. GLOBAL CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION

  • 9.1. INTRODUCTION
  • 9.2. INJECTABLE CONTRAST MEDIA
  • 9.3. ORAL CONTRAST MEDIA
  • 9.4. RECTAL CONTRAST MEDIA
  • 9.5. URETHRAL CONTRAST MEDIA

10. GLOBAL CONTRAST MEDIA/AGENTS MARKET, BY INDICATION

  • 10.1. INTRODUCTION
  • 10.2. CARDIOVASCULAR DISORDERS
  • 10.3. ONCOLOGY
  • 10.4. GASTROINTESTINAL DISORDERS
  • 10.5. NEUROLOGICAL DISORDERS
  • 10.6. NEPHROLOGICAL DISORDERS
  • 10.7. MUSCULOSKELETAL DISORDERS

11. GLOBAL CONTRAST MEDIA/AGENTS MARKET, BY APPLICATION

  • 11.1. INTRODUCTION
  • 11.2. RADIOLOGY
  • 11.3. INTERVENTIONAL CARDIOLOGY
  • 11.4. INTERVENTIONAL RADIOLOGY

12. CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY REGION

  • 12.1. INTRODUCTION
  • 12.2. NORTH AMERICA
    • 12.2.1. U.S.
      • 12.2.1.1. Increasing number of diagnostic imaging tests and centers
      • 12.2.1.2. Rising aging population, rising prevalence of chronic diseases
      • 12.2.1.3. Prevalence of Alzheimer's disease and other dementias
    • 12.2.2. CANADA
      • 12.2.2.1. Rising aging population, high incidence of cancer, CVD, and diabetes
      • 12.2.2.2. Increasing MRI and CT examinations
      • 12.2.2.3. Increasing research activities
  • 12.3. EUROPE
    • 12.3.1. EUROPE 5
      • 12.3.1.1. Increase in investments by market players
      • 12.3.1.2. Increasing incidence and prevalence of cancer
      • 12.3.1.3. U.K.: Lack of sufficient instruments
      • 12.3.1.4. Conferences/meetings/symposiums/workshops in Europe
    • 12.3.2. ROE
      • 12.3.2.1. Increase focus of market players on RoE countries
  • 12.4. ASIA-PACIFIC
    • 12.4.1. RISE IN AGING POPULATION AND CANCER INCIDENCE
    • 12.4.2. EXPANSION OF INTERNATIONAL PLAYERS IN CHINA AND INDIA
    • 12.4.3. INCREASING R&D INVESTMENTS IN CHINA
    • 12.4.4. FAVORABLE REGULATORY CHANGES IN NEW ZEALAND AND AUSTRALIA
    • 12.4.5. INCREASING RESEARCH ACTIVITIES IN ASIA-PACIFIC
  • 12.5. REST OF THE WORLD
    • 12.5.1. LATIN AMERICA
    • 12.5.2. THE MIDDLE EAST
    • 12.5.3. AFRICA

13. COMPETITIVE LANDSCAPE

  • 13.1. OVERVIEW
  • 13.2. MARKET SHARE ANALYSIS
    • 13.2.1. BAYER HEALTHCARE
    • 13.2.2. GE HEALTHCARE
  • 13.3. COMPETITIVE SCENARIO
    • 13.3.1. MARKET DEVELOPMENTS (PRODUCT APPROVALS)
    • 13.3.2. AGREEMENTS, COLLABORATIONS, CONTRACTS, AND PARTNERSHIPS
    • 13.3.3. EXPANSIONS
    • 13.3.4. OTHER STRATEGIES

14. COMPANY PROFILES (Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*

  • 14.1. INTRODUCTION
  • 14.2. GE HEALTHCARE
  • 14.3. BAYER AG
  • 14.4. BRACCO IMAGING S.P.A.
  • 14.5. GUERBET GROUP
  • 14.6. LANTHEUS MEDICAL IMAGING (SUBSIDIARY OF LANTHEUS HOLDINGS, INC.)
  • 14.7. NANOPET PHARMA GMBH
  • 14.8. CMC CONTRAST AB
  • 14.9. DAIICHI SANKYO
  • 14.10. SUBHRA PHARMA PRIVATE LIMITED
  • 14.11. SPAGO NANOMEDICAL AB

*Details on MarketsandMarkets view, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments might not be captured in case of unlisted companies.

15. APPENDIX

  • 15.1. DISCUSSION GUIDE
  • 15.2. OTHER DEVELOPMENTS
  • 15.3. KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 15.4. INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
  • 15.5. AVAILABLE CUSTOMIZATIONS
  • 15.6. RELATED REPORTS

LIST OF TABLES

  • TABLE 1: INDICATIVE LIST OF RESEARCH STUDIES UNDERTAKEN BY RESEARCH INSTITUTES AND UNIVERSITIES
  • TABLE 2: INDICATIVE LIST OF CLINICAL TRIALS CONDUCTED FOR CONTRAST MEDIA
  • TABLE 3: INDICATIVE LIST OF PRODUCT PIPELINE FOR CONTRAST MEDIA
  • TABLE 4: CONTRAST MEDIA MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 5: IODINATED CONTRAST MEDIA MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 6: GADOLINIUM-BASED CONTRAST MEDIA MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 7: MICROBUBBLE CONTRAST MEDIA MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 8: BARIUM-BASED CONTRAST MEDIA MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 9: CONTRAST MEDIA MARKET SIZE, BY MEDICAL PROCEDURE, 2014-2021 (USD MILLION)
  • TABLE 10: CONTRAST MEDIA MARKET SIZE FOR X-RAY/CT PROCEDURES, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 11: CONTRAST MEDIA MARKET SIZE FOR MRI PROCEDURES, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 12: CONTRAST MEDIA MARKET SIZE FOR ULTRASOUND PROCEDURES, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 13: CONTRAST MEDIA/CONTRAST AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2014-2021 (USD MILLION)
  • TABLE 14: INJECTABLE CONTRAST MEDIA/CONTRAST AGENTS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 15: ORAL CONTRAST MEDIA/CONTRAST AGENTS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 16: RECTAL CONTRAST MEDIA/CONTRAST AGENTS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 17: URETHRAL CONTRAST MEDIA/CONTRAST AGENTS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 18: CONTRAST MEDIA MARKET SIZE, BY INDICATION, 2014-2021 (USD MILLION)
  • TABLE 19: CONTRAST MEDIA MARKET SIZE FOR CARDIOVASCULAR DISORDERS, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 20: CONTRAST MEDIA MARKET SIZE FOR ONCOLOGY, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 21: CONTRAST MEDIA MARKET SIZE FOR GASTROINTESTINAL DISORDERS, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 22: CONTRAST MEDIA MARKET SIZE FOR NEUROLOGICAL DISORDERS, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 23: CONTRAST MEDIA MARKET SIZE FOR NEPHROLOGICAL DISORDERS, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 24: CONTRAST MEDIA MARKET SIZE FOR MUSCULOSKELETAL DISORDERS, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 25: CONTRAST MEDIA MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 26: CONTRAST MEDIA MARKET SIZE FOR RADIOLOGY, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 27: CONTRAST MEDIA MARKET SIZE FOR INTERVENTIONAL CARDIOLOGY, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 28: CONTRAST MEDIA MARKET SIZE FOR INTERVENTIONAL RADIOLOGY, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 29: CONTRAST MEDIA MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 30: NORTH AMERICA: CONTRAST MEDIA MARKET SIZE, BY PROCEDURE, 2014-2021 (USD MILLION)
  • TABLE 31: NORTH AMERICA: CONTRAST MEDIA MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 32: NORTH AMERICA: CONTRAST MEDIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2014-2021 (USD MILLION)
  • TABLE 33: NORTH AMERICA: CONTRAST MEDIA MARKET SIZE, BY INDICATION, 2014-2021 (USD MILLION)
  • TABLE 34: NORTH AMERICA: CONTRAST MEDIA MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 35: U.S.: CONTRAST MEDIA MARKET SIZE, BY PROCEDURE, 2014-2021 (USD MILLION)
  • TABLE 36: U.S.: CONTRAST MEDIA MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 37: U.S.: CONTRAST MEDIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2014-2021 (USD MILLION)
  • TABLE 38: U.S.: CONTRAST MEDIA MARKET SIZE, BY INDICATION, 2014-2021 (USD MILLION)
  • TABLE 39: U.S.: CONTRAST MEDIA MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 40: RESEARCH PROJECTS IN CANADA, 2013-2016
  • TABLE 41: CANADA: CONTRAST MEDIA MARKET SIZE, BY PROCEDURE, 2014-2021 (USD MILLION)
  • TABLE 42: CANADA: CONTRAST MEDIA MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 43: CANADA: CONTRAST MEDIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2014-2021 (USD MILLION)
  • TABLE 44: CANADA: CONTRAST MEDIA MARKET SIZE, BY INDICATION, 2014-2021 (USD MILLION)
  • TABLE 45: CANADA: CONTRAST MEDIA MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 46: EUROPE: CONTRAST MEDIA MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 47: EUROPE: CONTRAST MEDIA MARKET SIZE, BY PROCEDURE, 2014-2021 (USD MILLION)
  • TABLE 48: EUROPE: CONTRAST MEDIA MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 49: EUROPE: CONTRAST MEDIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2014-2021 (USD MILLION)
  • TABLE 50: EUROPE: CONTRAST MEDIA MARKET SIZE, BY INDICATION, 2014-2021 (USD MILLION)
  • TABLE 51: EUROPE: CONTRAST MEDIA MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 52: INDICATIVE LIST OF UPCOMING EVENTS IN EUROPE
  • TABLE 53: EUROPE 5: CONTRAST MEDIA MARKET SIZE, BY PROCEDURE, 2014-2021 (USD MILLION)
  • TABLE 54: EUROPE 5: CONTRAST MEDIA MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 55: EUROPE 5: CONTRAST MEDIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2014-2021 (USD MILLION)
  • TABLE 56: EUROPE 5: CONTRAST MEDIA MARKET SIZE, BY INDICATION, 2014-2021 (USD MILLION)
  • TABLE 57: EUROPE 5: CONTRAST MEDIA MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 58: ROE: CONTRAST MEDIA MARKET SIZE, BY PROCEDURE, 2014-2021 (USD MILLION)
  • TABLE 59: ROE: CONTRAST MEDIA MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 60: ROE: CONTRAST MEDIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2014-2021 (USD MILLION)
  • TABLE 61: ROE: CONTRAST MEDIA MARKET SIZE, BY INDICATION 2014-2021 (USD MILLION)
  • TABLE 62: ROE: CONTRAST MEDIA MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 63: RESEARCH PROJECTS IN ASIA-PACIFIC, 2013-2016
  • TABLE 64: APAC: CONTRAST MEDIA MARKET SIZE, BY PROCEDURE, 2014-2021 (USD MILLION)
  • TABLE 65: APAC: CONTRAST MEDIA MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 66: APAC: CONTRAST MEDIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2014-2021 (USD MILLION)
  • TABLE 67: APAC: CONTRAST MEDIA MARKET SIZE, BY INDICATION 2014-2021 (USD MILLION)
  • TABLE 68: APAC: CONTRAST MEDIA MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 69: ROW: CONTRAST MEDIA MARKET SIZE, BY PROCEDURE, 2014-2021 (USD MILLION)
  • TABLE 70: ROW: CONTRAST MEDIA MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 71: ROW: CONTRAST MEDIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2014-2021 (USD MILLION)
  • TABLE 72: ROW: CONTRAST MEDIA MARKET SIZE, BY INDICATION 2014-2021 (USD MILLION)
  • TABLE 73: ROW: CONTRAST MEDIA MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 74: MARKET DEVELOPMENTS (PRODUCT APPROVALS), 2013-2016
  • TABLE 75: AGREEMENTS, COLLABORATIONS, CONTRACTS, AND PARTNERSHIPS, 2013-2016
  • TABLE 76: EXPANSIONS, 2013-2016
  • TABLE 77: OTHER STRATEGIES, 2013-2016

LIST OF FIGURES

  • FIGURE 1: RESEARCH METHODOLOGY: GLOBAL CONTRAST MEDIA/CONTRAST AGENTS MARKET
  • FIGURE 2: BREAK DOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 3: SAMPLING FRAME: PRIMARY RESEARCH
  • FIGURE 4: KEY DATA FROM PRIMARY SOURCES
  • FIGURE 5: MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH
  • FIGURE 6: MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
  • FIGURE 7: RESEARCH DESIGN: GLOBAL CONTRAST MEDIA/ CONTRAST AGENTS MARKET
  • FIGURE 8: DATA TRIANGULATION METHODOLOGY
  • FIGURE 9: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY PROCEDURE (2016)
  • FIGURE 10: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2016 VS. 2021
  • FIGURE 11: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION, 2016 VS. 2021
  • FIGURE 12: CONTRAST MEDIA/CONTRAST AGENTS MARKET ANALYSIS, BY APPLICATION, 2016 VS. 2021
  • FIGURE 13: EUROPE IS SLATED TO WITNESS THE HIGHEST GROWTH IN THE CONTRAST MEDIA/CONTRAST AGENTS MARKET DURING THE FORECAST PERIOD
  • FIGURE 14: NORTH AMERICA TO ACCOUNT FOR THE LARGEST MARKET SHARE IN 2016
  • FIGURE 15: IODINATED CONTRAST MEDIA SEGMENT TO DOMINATE THE MARKET IN 2016
  • FIGURE 16: EUROPE TO WITNESS HIGHEST GROWTH DURING THE FORECAST PERIOD
  • FIGURE 17: CARDIOVASCULAR DISORDERS TO COMMAND THE LARGEST MARKET SHARE IN 2016
  • FIGURE 18: DRIVERS, RESTRAINTS, OPPORTUNITIES, & CHALLENGES
  • FIGURE 19: CLINICAL TRIALS FOR CONTRAST MEDIA/CONTRAST AGENTS, BY PHASE
  • FIGURE 20: CLINICAL TRIALS FOR CONTRAST MEDIA/CONTRAST AGENTS, BY INDICATION (2013-2016)
  • FIGURE 21: MICROBUBBLE CONTRAST MEDIA TO FORM THE FASTEST-GROWING SEGMENT DURING THE FORECAST PERIOD
  • FIGURE 22: X-RAY/CT ACCOUNTS FOR THE LARGEST SHARE OF THE CONTRAST MEDIA MARKET
  • FIGURE 23: INJECTABLE CONTRAST MEDIA/CONTRAST AGENTS ARE THE LARGEST AND FASTEST-GROWING SEGMENT IN THE CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION
  • FIGURE 24: CARDIOVASCULAR DISORDERS TO DOMINATE THE CONTRAST MEDIA MARKET
  • FIGURE 25: RADIOLOGY TO ACCOUNT FOR THE LARGEST SHARE OF THE CONTRAST MEDIA MARKET, BY APPLICATION (2016)
  • FIGURE 26: NORTH AMERICA COMMANDED THE LARGEST SHARE OF THE CONTRAST MEDIA MARKET
  • FIGURE 27: NORTH AMERICA: CONTRAST MEDIA MARKET SNAPSHOT
  • FIGURE 28: PREVALENCE OF ALZHEIMER'S DISEASE IN THE U.S., BY AGE GROUP, 2015
  • FIGURE 29: EUROPE: CONTRAST MEDIA MARKET SNAPSHOT
  • FIGURE 30: ASIA-PACIFIC: CONTRAST MEDIA MARKET SNAPSHOT
  • FIGURE 31: ROW: CONTRAST MEDIA MARKET SNAPSHOT
  • FIGURE 32: GLOBAL CONTRAST MEDIA MARKET SHARE, BY KEY PLAYER, 2015
  • FIGURE 33: KEY DEVELOPMENTS OF THE PROMINENT PLAYERS IN THE CONTRAST MEDIA MARKET (2013-2016)
  • FIGURE 34: MARKET DEVELOPMENTS (PRODUCT APPROVALS)- KEY GROWTH STRATEGY ADOPTED BY MARKET PLAYERS FROM 2013 TO 2016
  • FIGURE 35: PRODUCT MIX OF THE PROMINENT PLAYERS IN THE CONTRAST MEDIA MARKET
  • FIGURE 36: GE HEALTHCARE: COMPANY SNAPSHOT
  • FIGURE 37: BAYER HEALTHCARE: COMPANY SNAPSHOT
  • FIGURE 38: GUERBET GROUP: COMPANY SNAPSHOT
  • FIGURE 39: LANTHEUS MEDICAL IMAGING: COMPANY SNAPSHOT
  • FIGURE 40: DAIICHI SANKYO: COMPANY SNAPSHOT
  • FIGURE 41: SPAGO NANOMEDICAL AB: COMPANY SNAPSHOT
Back to Top